A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA).

2015 
e15124 Background: Advanced CCA carries a poor prognosis, and no standard treatment exists beyond the first line gemcitabine/platinum-based regimen. We performed a single arm phase II and biomarker...
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []